Galecto Biotech secures €79m in Series C funding to advance idiopathic pulmonary fibrosis treatment

Galecto Biotech, a Denmark-based pharmaceutical company specializing in galectin modulators for severe diseases like idiopathic pulmonary fibrosis (IPF) and cancer, has successfully raised €79 million ... Read More